Cargando…

Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy

BACKGROUND: Mood and anxiety symptoms in chronic hepatitis C (CHC) may be related to the patient awareness of the diagnosis and prognosis, to side effects induced by interferon (IFN)-alpha treatment, as well as to substance abuse. However, the observation of metabolic alterations in patients with CH...

Descripción completa

Detalles Bibliográficos
Autores principales: Carta, Mauro G, Hardoy, Maria Carolina, Garofalo, Alessandra, Pisano, Enrica, Nonnoi, Valentina, Intilla, Gesuina, Serra, Giancarlo, Balestrieri, Cinzia, Chessa, Luchino, Cauli, Cristiana, Lai, Maria Eliana, Farci, Patrizia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2203967/
https://www.ncbi.nlm.nih.gov/pubmed/17956625
http://dx.doi.org/10.1186/1745-0179-3-22
_version_ 1782148402935496704
author Carta, Mauro G
Hardoy, Maria Carolina
Garofalo, Alessandra
Pisano, Enrica
Nonnoi, Valentina
Intilla, Gesuina
Serra, Giancarlo
Balestrieri, Cinzia
Chessa, Luchino
Cauli, Cristiana
Lai, Maria Eliana
Farci, Patrizia
author_facet Carta, Mauro G
Hardoy, Maria Carolina
Garofalo, Alessandra
Pisano, Enrica
Nonnoi, Valentina
Intilla, Gesuina
Serra, Giancarlo
Balestrieri, Cinzia
Chessa, Luchino
Cauli, Cristiana
Lai, Maria Eliana
Farci, Patrizia
author_sort Carta, Mauro G
collection PubMed
description BACKGROUND: Mood and anxiety symptoms in chronic hepatitis C (CHC) may be related to the patient awareness of the diagnosis and prognosis, to side effects induced by interferon (IFN)-alpha treatment, as well as to substance abuse. However, the observation of metabolic alterations in patients with CHC has led to hypothesize a direct effect of hepatitis C virus (HCV) on brain function. This study was aimed at elucidating whether CHC is associated with specific anxiety or mood disorders independently of confounding factors. METHODS: Patient cohort: consecutive patients, 135 with CHC and 76 with chronic hepatitis B (CHB). Exclusion criteria: previous treatment with IFN-alpha, co-infection with HCV and hepatitis B virus, infection with human immunodeficiency virus, drug or alcohol abuse, or malignancies. Controls: subjects without evidence of hepatitis randomly extracted from the database of a previous epidemiological study; they were divided into two groups of 540 (332 males) and 304 (220 males) as controls for patients with CHC and CHB, respectively. The psychiatric diagnosis was formulated by means of the Composite International Diagnostic Interview Simplified carried out by a physician according to DSM-IV criteria. RESULTS: A higher lifetime prevalence of major depressive disorder (MDD) was observed among CHC compared to CHB or controls. The risk of MDD was not statistically different between CHB and controls. Both the CHC and CHB groups showed a significantly higher frequency of panic disorder when compared to controls. No statistical differences were observed in the prevalence of general anxiety disorder and social phobia when CHC or CHB were compared to controls. CONCLUSION: The present study provides the first evidence of an association between CHC and MDD, diagnosed on the basis of well-defined international criteria. This association is independent of treatment with IFN-alpha and is not influenced by substance or alcohol abuse. By contrast, anxiety disorders do not appear to be specifically associated with CHC.
format Text
id pubmed-2203967
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22039672008-01-17 Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy Carta, Mauro G Hardoy, Maria Carolina Garofalo, Alessandra Pisano, Enrica Nonnoi, Valentina Intilla, Gesuina Serra, Giancarlo Balestrieri, Cinzia Chessa, Luchino Cauli, Cristiana Lai, Maria Eliana Farci, Patrizia Clin Pract Epidemiol Ment Health Research BACKGROUND: Mood and anxiety symptoms in chronic hepatitis C (CHC) may be related to the patient awareness of the diagnosis and prognosis, to side effects induced by interferon (IFN)-alpha treatment, as well as to substance abuse. However, the observation of metabolic alterations in patients with CHC has led to hypothesize a direct effect of hepatitis C virus (HCV) on brain function. This study was aimed at elucidating whether CHC is associated with specific anxiety or mood disorders independently of confounding factors. METHODS: Patient cohort: consecutive patients, 135 with CHC and 76 with chronic hepatitis B (CHB). Exclusion criteria: previous treatment with IFN-alpha, co-infection with HCV and hepatitis B virus, infection with human immunodeficiency virus, drug or alcohol abuse, or malignancies. Controls: subjects without evidence of hepatitis randomly extracted from the database of a previous epidemiological study; they were divided into two groups of 540 (332 males) and 304 (220 males) as controls for patients with CHC and CHB, respectively. The psychiatric diagnosis was formulated by means of the Composite International Diagnostic Interview Simplified carried out by a physician according to DSM-IV criteria. RESULTS: A higher lifetime prevalence of major depressive disorder (MDD) was observed among CHC compared to CHB or controls. The risk of MDD was not statistically different between CHB and controls. Both the CHC and CHB groups showed a significantly higher frequency of panic disorder when compared to controls. No statistical differences were observed in the prevalence of general anxiety disorder and social phobia when CHC or CHB were compared to controls. CONCLUSION: The present study provides the first evidence of an association between CHC and MDD, diagnosed on the basis of well-defined international criteria. This association is independent of treatment with IFN-alpha and is not influenced by substance or alcohol abuse. By contrast, anxiety disorders do not appear to be specifically associated with CHC. BioMed Central 2007-10-23 /pmc/articles/PMC2203967/ /pubmed/17956625 http://dx.doi.org/10.1186/1745-0179-3-22 Text en Copyright ©2007 Carta et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Carta, Mauro G
Hardoy, Maria Carolina
Garofalo, Alessandra
Pisano, Enrica
Nonnoi, Valentina
Intilla, Gesuina
Serra, Giancarlo
Balestrieri, Cinzia
Chessa, Luchino
Cauli, Cristiana
Lai, Maria Eliana
Farci, Patrizia
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
title Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
title_full Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
title_fullStr Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
title_full_unstemmed Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
title_short Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
title_sort association of chronic hepatitis c with major depressive disorders: irrespective of interferon-alpha therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2203967/
https://www.ncbi.nlm.nih.gov/pubmed/17956625
http://dx.doi.org/10.1186/1745-0179-3-22
work_keys_str_mv AT cartamaurog associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT hardoymariacarolina associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT garofaloalessandra associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT pisanoenrica associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT nonnoivalentina associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT intillagesuina associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT serragiancarlo associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT balestriericinzia associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT chessaluchino associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT caulicristiana associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT laimariaeliana associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy
AT farcipatrizia associationofchronichepatitiscwithmajordepressivedisordersirrespectiveofinterferonalphatherapy